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Background: To evaluate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the treatment of
neovascular age-related macular degeneration in subjects with or without diabetes mellitus.
Methods: A pooled, retrospective, analysis was conducted of data from 9 sponsor-administered, randomized, open-
label trials. Subjects who received pegaptanib by randomization or change in dose assignment, crossover design, or
protocol amendment, were included. Reports of endophthalmitis, increased intraocular pressure, retinal injury,
intraocular hemorrhage, traumatic cataract, hypersensitivity reactions, stroke, myocardial infarction, and other arterial
thromboembolic events defined by the Antiplatelet Trialists’ Collaboration were identified by Medical Dictionary for
Regulatory Activities preferred terms. Adverse events were summarized from the first injection to 42 days after the
last injection. The incidence of adverse events was stratified by the presence/absence of diabetes.
Results: Of 1,586 subjects enrolled, 165 (10.4%) had a history of diabetes mellitus and 1,421 (89.6%) did not. The 2
populations were similar at baseline. Based on the comparison of prespecified ocular, hypersensitivity, and
Antiplatelet Trialists’ Collaboration event terms, the safety review did not identify any notable differences between
the 2 populations.
Conclusions: This retrospective analysis found no increased safety risk resulting from treatment with pegaptanib
0.3 mg in individuals with neovascular age-related macular degeneration and concomitant diabetes mellitus.Background
Inflammation is thought to play an important role in the
pathophysiology of diabetic retinopathy (DR) [1-3] with
elevated levels of vascular endothelial growth factor
(VEGF) being a key mediator [4]. The off-label intravi-
treal use of VEGF antagonists (with the exception of
ranibizumab, which is currently approved in Europe) in
the treatment of DR and diabetic macular edema (DME)
appears to result in vision gains and reductions in cen-
tral macular thickness [5,6]. Pegaptanib sodium is a
selective VEGF antagonist first approved in the United
States for the treatment of age-related macular degener-
ation (AMD) in December 2005. In retrospective studies* Correspondence: Theresa.Dombi@Pfizer.com
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reproduction in any medium, provided the orof pegaptanib sodium, significant reductions in central
macular thickness and changes in visual acuity were
reported in subjects with DME compared to baseline [7]
and compared to laser alone [8]. Intravitreal pegapta-
nib also has been used to delay or abrogate the need
for vitrectomy for recurrent and nonclearing vitreous
hemorrhage in proliferative DR in a consecutive case
series [9].
The diabetic population is at an increased risk of vas-
cular complications, including myocardial infarction
[10], stroke [11-14], coronary heart disease [14,15], and
peripheral artery disease [16]. Although pegaptanib has
an established long-term safety record in subjects with
neovascular AMD [17,18] the question arises as to
whether or not the intraocular administration of anti-
VEGF agents in the diabetic population poses an add-
itional systemic risk. Because there is a lack of large,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-VEGF therapies, understanding the implications of
administering these agents in individuals with diabetes is
important information for the clinician. This retrospect-
ive analysis was performed to evaluate the safety of
pegaptanib in the subset of patients with diabetes who
were receiving pegaptanib for AMD (data on file, Pfizer
Inc) [19,20].
Methods
This pooled retrospective analysis evaluated the occur-
rence of prespecified adverse events in subjects with or
without diabetes mellitus (type 1 and type 2) who were
treated with pegaptanib sodium injection (Macugen,
Eyetech Inc) for AMD. All subjects who received study
treatment with pegaptanib 0.3 mg by intravitreal injec-
tion in the Phase II through Phase IV clinical trials by
way of randomization assignment, crossover design,
protocol amendment, or change in dose assignment
were included in the analysis (Table 1). These studies
were conducted in full conformance with the principles
of the Declaration of Helsinki or with the laws of
the country in which the research was conducted,
whichever afforded the greater protection to the
study participant. Institutional Review Board or Ethics
Committee approval was obtained from each clinical
center and signed informed consent was obtained from




NCT00321997 (EOP1003; randomized) Up to 5 years Pegaptanib 0.3, 1
NCT00021736 (EOP1004; randomized) Up to 5 years Pegaptanib 0.3, 1
NCT00215670 (EOP1006; randomized) Up to 2 years Pegaptanib 0.3
NCT00087763 (EOP1009; randomized) 1 year; with no
treatment
weeks 12 to 24
Pegaptanib 0.3,
NCT00088192 (EOP1010; open-label) Up to 3 years Pegaptanib




Up to 4 years Pegaptanib 0
NCT00324116 (A5751016; open-label) 1 year Pegaptanib
NCT00327470 (A5751017; open-label) Up to 2 years Pegaptanib
PDT: photodynamic therapy with verteporfin.
*Unpublished observation ([by author or pharma, year]).
**Unpublished results; trial terminated.
***Study A5751015 was an extension of study A5751010 and were considered as a
†Unpublished observations (Estephan M, Troy S, Starita C, for the French Macugen i
Specialists - 10th EURETINA Congress. Paris, France; 2010: Poster 1016).In studies where subjects received 0.3 mg doses and/
or other doses (sham or pegaptanib 1 mg or 3 mg), only
the period when they received the 0.3 mg dose was
included for compiling data on treatment exposure,
adverse events, concomitant medications and disconti-
nuations. The treatment-exposure period was defined as
the time from the first pegaptanib 0.3 mg injection to
42 days after the last injection.
Standard summary tables filtered by the prespecified
treatment-emergent adverse event MedDRA [Medical
Dictionary for Regulatory Activities, version 12.1] pre-
ferred terms (PTs) (Table 2) were prepared. These
included endophthalmitis, increased intraocular pressure
(IOP), retinal injury, intraocular hemorrhage, traumatic
cataract, hypersensitivity reactions, stroke, myocardial
infarction, and other cardiovascular and cerebrovascular
thromboembolic events [21,22]. The ocular and nonocu-
lar (hypersensitivity) terms were those used to identify
the ocular and hypersensitivity risks for pegaptanib in
the risk management plan and for which the sponsor
conducts regular pharmacovigilance monitoring. The
cardiovascular, cerebrovascular and peripheral vascular
arterial thromboembolic events listed were selected
based on Antiplatelet Trialists’ Collaboration (APTC)
criteria [21,22] and are the terms followed as part of
routine pharmacovigilance by the sponsor. In order
to detect whether the clinical database contained any of
the prespecified treatment-emergent PTs, each PT wasects received 0.3 mg pegaptanib









, 3 mg; sham 22 (13.3%) 208 (14.6%) 7 (26.9%) [15]
, 3 mg; sham 20 (12.1%) 182 (12.8%) 14 (53.8%) [17]
, 1, 3 mg 1 (0.6%) 41 (2.9%) 0 (0%) [29]
1 mg; sham 4 (2.4%) 60 (4.2%) 5 (19.2%) *
0.3 mg 67 (40.6%) 370 (26.0%) 0 (0%) [30]
0.3 mg;
mg+ PDT
16 (9.7%) 149 (10.5%) 0 (0%)
.3, 1 mg 7 (4.2%) 72 (5.1%) 0 (0%) [30]***
0.3 mg 11 (6.7%) 70 (4.9%) 0 (0%) †
0.3 mg 17 (10.3%) 269 (18.9%) 0 (0%) †
single study for this manuscript.
n Early Onset CNV Study Group presented at European Society of Retina





Intraocular pressure, increased Hypersensitivity NOS (v. 5.1)
Ocular hypertension Anaphylactic shock
Glaucoma Anaphylactic reaction
Glaucoma NOS (v. 5.1) Anaphylactoid shock
Glaucoma, traumatic Anaphylactoid reaction
Retinal injury Angioedema
Retinal tear Angioneurotic edema (v. 5.1)
Retinal detachment Blepharitis, allergic
Retinal hemorrhage Dermatitis, contact




Retinal pigment epitheliopathy (v. 5.1) Toxic epidermal necrolysis
Eye hemorrhage Lyell syndrome (v. 5.1)
Eye hemorrhage NOS (v. 5.1) Drug eruption
Vitreous hemorrhage Dermatitis medicamentosa (v. 5.1)
Cataract traumatic Erythema
Erythema multiforme Urticaria
Tongue edema Stevens-Johnson syndrome
Pharyngeal edema Stevens-Johnson syndrome (v. 5.1)
Laryngeal edema Rash
Latex allergy Rash NOS (v. 5.1)
Paresthesia oral Skin reaction
Paraesthesia mucosal Acute generalized
exanthematous pustulosis
Paraesthesia mucosal NOS (v. 5.1) Drug rash with eosinophilia
and systemic symptoms
Antiplatelet Trialists’ Collaboration Events
Cardiovascular Cerebrovascular
Acute myocardial infarction Brain stem infarction
Cardiac arrest Cerebrovascular accident
Cardiac failure congestive Lacunar infarction
Myocardial infarction Cerebral hemorrhage
Retroperitoneal hemorrhage Transient ischemic attack
Sudden death Peripheral vascular thrombosis
Silent myocardial infarction Pulmonary embolism
Coronary artery stenosis Deep vein thrombosis
Acute coronary syndrome Thrombosis
Angina pectoris Ischemia
Angina unstable Ischemia NOS (v. 5.1)
MedDRA: Medical Dictionary for Regulatory Activities.
NOS: not otherwise specified.
V: version.
Dombi et al. BMC Ophthalmology 2012, 12:37 Page 3 of 8
http://www.biomedcentral.com/1471-2415/12/37divided into a separate text string for extensive search
purposes so that if a PT recorded in the clinical database
contained any of the text strings, it was considered a
match. Any unrelated terms were removed after the
first-round review.
The frequency of prespecified treatment-emergent
event terms as well as other safety data reported by the
pooled AMD subjects with a medical history of diabetes
mellitus were compared with the corresponding data
reported by the pooled AMD subjects without a medical
history of diabetes mellitus. Events were categorized by
severity (mild, moderate, severe); in cases where the sub-
ject experienced the same event more than once, the
worst severity was presented.
Because sham injections were administered to subjects
with diabetes in 3 of the pooled studies, an additional
analysis of APTC events reported in this population was
conducted for comparison to pegaptanib-treated sub-
jects in the primary analysis. Events occurring in sub-
jects who received both pegaptanib and sham at
different time points in the study were counted twice if
the event was reported during each time period.
Results
Subject disposition and demographics
Nine sponsor-administered clinical studies, both rando-
mized and open-label of 1 to 5 years’ duration, in which
subjects received pegaptanib 0.3 mg were included in
the analysis. These consisted of all completed Phase II
through IV trials evaluating pegaptanib in AMD avail-
able at the time the plan for the pooled analysis was
finalized. There were 1,586 subjects enrolled, including
165 (10.4%) with diabetes and 1,421 (89.6%) without dia-
betes, receiving pegaptanib 0.3 mg. The number of
pegaptanib 0.3 mg injections received by the subjects
with and without diabetes was similar; the subjects with
diabetes received a mean of 8.8 injections (range, 1–39)
over a mean of 52.4 weeks and the subjects without dia-
betes received a mean of 9.7 injections (range, 1–44)
over a mean of 57.5 weeks. The diabetic population had
a higher percentage of males than the nondiabetic popu-
lation (51.5% vs. 42.6%) and a lower percentage of Cau-
casian/white subjects (44.2% vs. 61.3%, respectively); this
largely reflected a higher percentage of subjects with an
“unspecified” race in the diabetic population (47.9% vs.
31.6%, respectively). The mean age was similar between
groups (75.3 [range, 56–89] and 75.9 [range, 40–94]
years for the subjects with and without diabetes,
respectively).
Medical history
As expected, the group with diabetes had a greater pro-
portion of subjects with a medical history of metabolic
and vascular system disorders, including vascular
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ders/analyses; only cardiac arrhythmias and thyroid
gland disorders occurred more frequently in subjects
without diabetes. Most of the subjects with diabetes
(73.3%) and subjects without diabetes (66.1%) reported a
history of at least 1 ocular disease in the study eye, with
glaucoma and ocular hypertension occurring more fre-
quently in the subjects with diabetes than in those with-
out diabetes (11.5% vs. 7.9%, respectively). Subjects with
diabetes also had more eye therapeutic procedures than
those without diabetes (21.8% vs. 12.0%, respectively).
Early discontinuations from treatment
In all, 72 (43.6%) subjects in the diabetic group and 485
(34.8%) subjects in the nondiabetic group discontinued
treatment prematurely; causes and their reporting rates
were similar between groups. The majority of disconti-
nuations in the diabetic and nondiabetic groups were
due to lack of availability of the study drug (31 [18.8%]
and 167 [11.8%], respectively) and investigator or spon-
sor decision (22 [13.3%] and 171 [12%]). There were no
deaths leading to early discontinuation in the diabetic
group versus 11 (0.8%) in the nondiabetic group. Two
(1.2%) subjects in the diabetic group and 16 (1.1%) sub-
jects in the nondiabetic group discontinued due to ad-
verse events.
Adverse events leading to early discontinuation in
the diabetic group included 1 subject each with pneu-
monia not otherwise specified (NOS)/myocardial infarc-
tion (unrelated to study drug), and retinal hemorrhage/
cerebrovascular accident (causality not specified); both
events were fatal. In the nondiabetic group, ocular
adverse events leading to discontinuation were macular
degeneration including choroidal neovascularization (1
subject), retinal detachment (2 subjects), and visual acu-
ity reduced (3 subjects). Three adverse events resulted in
death and early discontinuation: metastatic cancer in 2
subjects and aortic aneurysm rupture in 1 subject; none
were related to the study drug. There were no notable
differences between the groups in events frequently asso-
ciated with diabetes; the subjects with diabetes reported
1 occurrence each of myocardial infarction, retinal
hemorrhage, and cerebrovascular accident and the sub-
jects without diabetes reported 1 occurrence each of ret-
inal tear and retinal hemorrhage, and 2 occurrences of
retinal detachment.
Treatment-emergent adverse events
Treatment-emergent adverse events (by System Organ
Class and PT) were reported by 117 (70.9%) and 1,095
(77.1%) of subjects in the diabetic and nondiabetic
groups, respectively, who received pegaptanib. The most
common treatment-emergent adverse events were eye
disorders, with similar reporting rates in both diabeticand nondiabetic groups (65.5% vs. 66.6%, respectively).
In order from highest to lowest, eye pain, reduced visual
acuity, punctate keratitis, and vitreous floaters were the
most frequent occurrences (reported in 15% to 22% of
subjects).
In general, there were no notable differences between
groups with respect to treatment-emergent, nonocular
adverse events. Among the nonocular adverse events,
arthralgia (3.6% vs. 2.4%), chest pain (2.4% vs. 1.2%), diz-
ziness (4.2% vs. 1.4%), aggravated hypertension (3.0% vs.
1.5%), nausea (3.0% vs. 1.8%), and vomiting NOS (4.2%
vs. 0.8%) were more frequently reported in subjects with
diabetes compared with subjects without diabetes, re-
spectively. Nasopharyngitis was more frequent in sub-
jects without diabetes (4.0%) compared with subjects
with diabetes (2.4%).
Prespecified ocular and hypersensitivity adverse events
In all, 28 (17.0%) subjects in the diabetic group reported
50 prespecified ocular adverse events and 294 (20.7%) in
the nondiabetic group reported 601 prespecified events
regardless of causality. The incidence and severity of
prespecified ocular adverse events (study eye) are shown
in Table 3. There were no differences between groups in
the incidence or severity of endophthalmitis, retinal de-
tachment, retinal hemorrhage, retinal tear, and vitreous
hemorrhage. Retinal pigment epitheliopathy was
reported more frequently in subjects with diabetes, and
IOP elevations were reported more frequently in the
subjects without diabetes. For injection- or therapy-
related ocular adverse events, no difference in the inci-
dence or severity of any event was found; 23 injection-
related events were reported by 15 (9.1%) subjects with
diabetes and 368 events were reported by 164 (11.5%)
subjects without diabetes. In all, 9 prespecified ocular
events related to study therapy were reported by 4
(2.4%) subjects with diabetes and 57 events were
reported by 43 (3.0%) subjects without diabetes. Rash
NOS was the only prespecified nonocular (hypersensitiv-
ity) adverse event that occurred in both subjects with
and without diabetes (1.2% vs. 0.8%, respectively). All
other hypersensitivity events were reported in subjects
without diabetes (Table 4).
Thromboembolic adverse events
Prespecified APTC adverse events irrespective of causality
were reported in 10 (6.1%) subjects with diabetes and in
60 (4.2%) subjects without diabetes. Serious APTC events
were reported by 6.1% and 3.4% of subjects with and with-
out diabetes, respectively, and severe APTC events were
reported by 3.6% and 2.4%, respectively. Cerebrovascular
accident was reported more frequently in the subjects
with diabetes than those without diabetes (1.8% vs. 0.6%,
respectively), while coronary artery atherosclerosis was
Table 3 Incidence and severity of prespecified ocular
adverse events in the study eye, all causality
Pegaptanib 0.3 mg
Subjects With Diabetes Without Diabetes
(N= 165 ) (N= 1,421)
Preferred Term1 n (%) Severe n (%) Severe
Cataract, traumatic 0 0 0 1 (0.1) 0
Detachment of retinal
pigment epithelium
0 0 0 3 (0.2) 0
Endophthalmitis 1 (0.6) 1 16 (1.1) 14
Eye hemorrhage 0 0 0 6 (0.4) 2
Eye hemorrhage NOS 0 0 0 3 (0.2) 0
Glaucoma 0 0 0 2 (0.1) 0
Glaucoma NOS 0 0 0 2 (0.1) 0
Intraocular pressure
increased
13 (7.9) 0 155 (10.9) 6
Ocular hypertension 0 0 0 11 (0.8) 0
Retinal detachment 1 (0.6) 0 9 (0.6) 5
Retinal hemorrhage 8 (4.8) 1 64 (4.5) 6
Retinal pigment
epitheliopathy
4 (2.4) 0 10 (0.7) 0
Retinal tear 1 (0.6) 0 0 (0.4) 0
Vitreous hemorrhage 3 (1.8) 0 21 (1.5) 2
1Preferred terms are from MedDRA [Medical Dictionary for Regulatory Activities,
version 12.1].
NOS: not otherwise specified.
Table 4 Incidence and severity of hypersensitivity




With Diabetes Without Diabetes
(N= 165) (N= 1421)
Preferred Term1 n (%) Severe LT n (%) Severe LT
Blepharitis, allergic 0 0 0 0 1 (0.1) 0 0
Dermatitis, allergic 0 0 0 0 1 (0.1) 0 0
Dermatitis, contact 0 0 0 0 7 (0.5) 0 0
Drug hypersensitivity 0 0 0 0 6 (0.4) 0 0
Erythema 0 0 0 0 2 (0.1) 0 0
Hypersensitivity 0 0 0 0 2 (0.1) 0 0
Hypersensitivity NOS 0 0 0 0 5 (0.4) 0 0
Rash 0 0 0 0 2 (0.1) 0 0
Rash NOS 2 (1.2) 0 0 12 (0.8) 0 0
Toxic skin eruption 0 0 0 0 1 (0.1) 0 0
Urticaria 0 0 0 0 1 (0.1) 0 0
1Preferred terms are from MedDRA [Medical Dictionary for Regulatory Activities,
version 12.1].
LT: life-threatening.
NOS: not otherwise specified.
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No life-threatening events occurred in the subjects with
diabetes while 11 (0.7%) were reported in the subjects
without diabetes receiving pegaptanib. However, it was
noted previously that 2 subjects with diabetes discontin-
ued treatment early: 1 due to myocardial infarction and
the other to a cerebrovascular accident; both had fatal out-
comes. No prespecified, injection-related APTC adverse
events were reported in either group. Cerebrovascular ac-
cident, the only study therapy related APTC event, was
reported in 1 (0.6%) subject with diabetes and 3 (0.2%)
subjects without diabetes.
The analysis identified 26 subjects with diabetes who
received sham injection in the 3 controlled studies; base-
line demographics were similar to those in the
pegaptanib-treated group with diabetes. One APTC
event was reported in 3 (11.5%) sham-treated subjects: a
life-threatening acute myocardial infarction; moderate
severity angina pectoris; severe congestive cardiac failure
(Table 5). No events led to death but 1 subject discon-
tinued therapy.
Deaths
In total, 6 (3.6%) subjects with diabetes and 28 (2.0%)
subjects without diabetes died during the studies. Death
was considered unrelated to treatment with pegaptanibin 33 cases; in 1 case death due to a ruptured abdominal
aortic aneurysm was considered treatment-related. The
most common causes of death were attributed to cardio-
vascular, cerebrovascular or peripheral vascular throm-
botic events. Deaths reported in the subjects with
diabetes included 1 occurrence of cerebrovascular acci-
dent deemed unknown in relationship to study drug
administration. Deaths attributed to vascular events in
the nondiabetic population included pulmonary embol-
ism (n = 3), myocardial infarction (n = 2), cerebrovascular
accident (n = 1), congestive heart failure (n = 2), cardiac/
cardiopulmonary arrest (n = 2), ischemic heart disease
(n = 2), cardiomyopathy (n = 1), and ruptured abdominal
aortic aneurysm (n = 2). The remainder of the deaths
were due to polytraumatism, respiratory failure/chronic
cardiopulmonary disease, gastric cancer and metastatic
colon and prostate cancers, brain metastasis, hypotension,
Clostridium difficile colitis, chronic obstructive pulmonary
disease, bronchopneumonia, and infection complicated by
cardiac and renal failure.
Discussion
In this retrospective examination of pooled adverse
events from AMD studies, subjects with diabetes, al-
though more susceptible to disease-related ocular and
thromboembolic events, had no increased risk as a result
of pegaptanib 0.3 mg therapy compared with those with-
out diabetes. Since only 10% of all subjects had diabetes,
comparisons between them and those without diabetes
were, at best, unbalanced. Given this limitation, we
Table 5 Incidence and severity of prespecified antiplatelet trialists’ collaboration events, all causality1
Pegaptanib sodium 0.3 mg Sham
Number of Subjects With Diabetes Without Diabetes With Diabetes
(N= 165) (N= 1421) (N = 26)
Preferred Term2 n (%) Sev LT n (%) Sev LT n (%) Sev Lt
Acute myocardial infarction 0 0 0 0 1 (0.1) 0 0 1 (3.8) 0 1
Angina pectoris 1 (0.6) 1 0 8 (0.6) 2 1 1 (3.8) 0 0
Angina unstable 0 0 0 0 4 (0.3) 2 0 0 0 0 0
Cardiac arrest 0 0 0 0 2 (0.1) 0 2 0 0 0 0
Cardiac failure congestive 0 0 0 0 5 (0.4) 1 2 1 (3.8) 1 0
Cerebral hemorrhage 0 0 0 0 1 (0.1) 0 1 0 0 0 0
Cerebrovascular accident 3 (1.8) 3 0 9 (0.6) 5 1 0 0 0 0
Coronary artery atherosclerosis 2 (1.2) 1 0 0 0 0 0 0 0 0 0
Coronary artery disease NOS 1 (0.6) 0 0 9 (0.6) 3 0 0 0 0 0
Coronary artery occlusion 0 0 0 0 1 (0.1) 1 0 0 0 0 0
Myocardial infarction 2 (1.2) 1 0 10 (0.7) 7 2 0 0 0 0
Pulmonary embolism 1 (0.6) 1 0 7 (0.5) 4 1 0 0 0 0
Retroperitoneal hemorrhage 0 0 0 0 1 (0.1) 1 0 1 (0.1) 1 0
Thrombosis 1 (0.6) 1 0 0 0 0 0 0 0 0 0
Transient ischemic attack 1 (0.6) 0 0 8 (0.6) 2 0 0 0 0 0
Silent myocardial infarction 1 (0.6) 0 0 0 0 0 0 0 0 0 0
Ischemia NOS 0 0 0 0 1 (0.1) 0 0 0 0 0 0
Deep vein thrombosis 0 0 0 0 4 (0.3) 1 0 0 0 0 0
1In cases in which subjects experienced the same event more than once, the worst severity was presented.
2Adverse event with a start date between the day of the first injection and at most 42 days after the last injection.
Preferred terms are from MedDRA [Medical Dictionary for Regulatory Activities, version 12.1].
LT: life-threatening.
NOS: not otherwise specified.
Sev: severe.
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and without diabetes in the frequencies of events in
general or in particular events related to diabetes
that were reported. Differences identified between the
groups involving adverse events that occurred more
often in subjects with diabetes were either expected or
were not considered important. The proportions of sub-
jects with diabetes reporting prespecified ocular adverse
events were similar to or less than the corresponding
proportions reported in the nondiabetic population.
The reporting rate and incidence of the prespecified
nonocular events (hypersensitivity reactions) were simi-
lar between the 2 groups.
The proportions of subjects with diabetes with prespe-
cified APTC adverse events were considered similar to
the proportions of those without diabetes with APTC
events. However, differences in individual arterial
thromboembolic adverse event terms between the 2
populations were identified. Cerebrovascular accident
and myocardial infarction were reported with a slightly
higher frequency in the subjects with diabetes. There
were also 3 events only reported by the diabeticpopulation: coronary artery atherosclerosis, thrombosis,
and silent myocardial infarction. In addition, a compari-
son of nonocular medical histories between the popula-
tions indicated that metabolic, vascular, and cardiac
disorders were reported more often in the subjects with
diabetes, and these disorders were consistent with those
generally experienced by a population with a history of
diabetes. Based on the deaths reported, there did not ap-
pear to be any increased risk of death to subjects with
diabetes mellitus as a result of pegaptanib treatment.
Although involving only a small population of people
with diabetes receiving sham treatment, these results
were further confirmed in the pooled analysis of the 3
studies in which subjects with diabetes were treated with
sham injections. Overall, there was no difference in the
occurrence of APTC events between subjects with dia-
betes receiving sham injections and those receiving
pegaptanib in the pooled analysis of 9 studies.
As the known properties of VEGF include angiogen-
esis, increased vascular permeability, and maintenance
of vascular endothelial integrity, there are a number of
theoretical risks that may be associated with systemic
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high dose bevacizumab in early clinical trials in oncology
was associated with potential complications of hyperten-
sion, proteinuria, impaired wound healing, gastrointes-
tinal perforation, hemorrhage and thrombosis [23]. The
systemic VEGF inhibition effects with pegaptanib are
not expected due to VEGF165 selectivity and low systemic
concentrations following intravitreal administration. In
the present study, although the frequency of APTCs
was low in both groups, subjects with diabetes appeared
to be at an elevated risk of certain APTC adverse
events compared to those without diabetes. Thus, the
potential for systemic effects following treatment for
AMD may be of greater concern in this population. In
a 3-year safety study of pegaptanib, there were no
thromboembolic cardiovascular accidents or nonocular
hemorrhagic events following continuous treatment [18]
while in a pooled analysis of data from the ranibizumab
trials there was a significantly increased risk of cardio-
vascular accidents [24] and nonocular hemorrhages [25]
in the treated group compared to sham. Bevacizumab
has been used increasingly off-label for treatment of
AMD [23]; the risk of these side effects following intra-
vitreal injection are not known due to the lack of sys-
tematic reporting [25-27]. Of note, in a study of
individuals with type 2 diabetes undergoing vitrectomy
following intravitreal injection of bevacizumab, mean
plasma VEGF concentrations were reduced approxi-
mately 10-fold (from 92.0 to 9.7 pg/ml) 1 day after in-
jection, clearly demonstrating entry into the systemic
circulation [28].
This retrospective examination of pooled adverse
events from AMD studies has certain strengths and lim-
itations. Its strengths include the large multinational
population from which the analysis is derived and the
rigorous study conduct and monitoring of adverse
events in these populations. As noted above, however,
the difference in size between the group with diabetes
and the group without did not provide a balanced com-
parison in terms of numbers. Other limitations include
combining study protocols that were of differing designs
and lengths and pooling clinical studies that were con-
ducted over a period of many years.Conclusions
Given consideration of the limitations of the analysis,
pegaptanib sodium exposure does not appear to result in
an increased risk for arterial thromboembolic or other
adverse systemic effects above what would be observed
in a sham-treated AMD population with cormorbid dia-
betes. There does not appear to be an incremental in-
crease in the risk of APTC events in AMD subjects with
diabetes due to treatment with pegaptanib.Competing interests
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